Trevi Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 20, 2024
TRVI$14.33+11.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Operating expenses: | ||
| Research and development | $23,683 | $19,834 |
| General and administrative | 10,240 | 10,073 |
| Total operating expenses | 33,923 | 29,907 |
| Loss from operations | (33,923) | (29,907) |
| Other income (expense): | ||
| Interest income, net | 4,748 | 1,740 |
| Other income, net | 469 | 289 |
| Interest expense | (391) | (1,163) |
| Change in fair value of term loan derivative liability | — | (147) |
| Total other income, net | 4,826 | 719 |
| Loss before income taxes | (29,097) | (29,188) |
| Income tax benefit | 32 | 36 |
| Net loss | $(29,065) | $(29,152) |
| Basic and diluted net loss per common share outstanding | $(0.29) | $(0.45) |
| Weighted average common shares used in net loss per share attributable to common stockholders, basic and diluted | 99,033,373 | 64,541,911 |
| Net loss | $(29,065) | $(29,152) |
| Other comprehensive loss: | ||
| Net unrealized gains (losses) on available-for-sale marketable securities | 93 | (122) |
| Comprehensive loss | $(28,972) | $(29,274) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.